Why Did GLSI Stock Rise Pre-Market Today?

• CEO Snehal Patel said the FDA has already reviewed plans to expand the trial to include all patient types, with over 1,300 patients enrolled.
• Data presented at the AACR Annual Meeting 2026 showed a near 4x jump in immune response 
• All patient types tested showed stronger immune responses after vaccination, with some improving 2- to 8-fold compared to before treatment.

Shares of Greenwich LifeSciences (GLSI) rose by more than 2% in premarket trading on Monday after the company unveiled new late-stage data that showed its breast cancer vaccine candidate could work across a broader patient population than previously expected. This could help expand its commercial opportunities.

The update, presented at the AACR Annual Meeting 2026, showed encouraging immune responses in patients outside the company’s originally targeted genetic subgroup.

Results From Phase III FLAMINGO-01 Trial

Originally, in its phase 3 FLAMINGO-01 trial, the company tested its vaccine, GLSI-100, only in patients with a specific genetic profile, HLA-A*02. However, new data from an open label arm in non-HLA-A*02 patients shows it may have a wider applicability.

GLSI said its Delayed-type-hypersensitivity (DTH) immune responses, which is a key measure of immune activation, jumped fourfold from month 4 to 6 of treatment in the specific patient cohort, the non-HLA-A02 arm. 

The biopharma firm also said that patients treated with GLSI-100 were increasingly able to mount an immune response to GP2 (the cancer protein fragment in the vaccine) as evidenced in this preliminary data.

All patient types tested showed stronger immune responses after vaccination, with some improving 2- to 8-fold compared to before treatment.

Snehal Patel, Chief Executive Officer at Greenwich LifeSciences said, the FDA has already reviewed plans to combine patient groups into a unified trial arm. The company has enrolled over 1,300 patients so far and may pursue approval across both populations using pooled data.

“The company will have the option to pursue approval for both HLA-A02 and non-HLA-A02 patients together using the increased statistical power of a combined analysis", said Snehal Patel. 

How Did Retail Traders React?

On Stocktwits, the retail sentiment surrounding the stock is ‘bullish’ amid ‘high’ message volumes.

Shares of Greenwich Lifesciences have risen over 28% year-to-date.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: CMND Stock Set For Biggest Intraday Gains In Over Three Years — Here’s Why Retail Is Eyeing Further Upside